Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence

Obesity Science & Practice
Ginger S CarlsWilliam H Polonsky

Abstract

The study aims to examine real-world weight change and the role of medication adherence among patients with type 2 diabetes who initiated one of three drug classes: glucagon-like peptide-1 receptor agonist (GLP-1RA), dipeptidyl peptidase-4 inhibitor (DPP4) and sulfonylureas (SUs). A cohort of patients initiating one of the three drug classes was selected from a large US database of integrated electronic medical record and administrative claims. Adherence was defined as per cent of days covered ≥80% during the year following drug initiation. Weight change was calculated from drug initiation (-180, +30 d) to 1 year (±90 d) later. Multivariate regression controlled for baseline differences between adherent and poorly adherent patients and the addition of another drug class during follow-up. The study included 833 GLP-1RA, 2,272 DPP4 and 2,713 SU patients who contributed 2,279, 6,602 and 7,429 observations respectively. Patients initiating a GLP-1RA achieved the largest weight change (-2.46 kg of GLP-1RA, -1.26 kg of DPP4 and 0.18 kg of SU, P < 0.01). Adherent GLP-1 patients lost 1.73 kg more than poorly adherent patients, and adherent SU patients gained 1.11 kg more than poorly adherent patients (all P < 0.01). Adherent and poorly...Continue Reading

References

Sep 27, 2006·Archives of Internal Medicine·P Michael HoDavid J Magid
Nov 16, 2011·The New England Journal of Medicine·Thomas A WaddenReneé H Moore
Nov 17, 2011·The New England Journal of Medicine·Lawrence J AppelFrederick L Brancati
Feb 20, 2014·International Journal of Clinical Practice·J P H Wilding
Apr 29, 2016·Journal of Managed Care & Specialty Pharmacy·Jayanti MukherjeeStephen Johnston
Dec 17, 2016·Diabetes Care·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Citations

May 6, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Carol M HamerskyNeeraj N Iyer
Nov 27, 2019·Diabetic Medicine : a Journal of the British Diabetic Association·R Dankner, J Roth
Mar 10, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Bruno GuerciElisheva Lew
Sep 26, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Antonio C BossiUNKNOWN ANDREW study group
Nov 19, 2020·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Mario Luca MorieriGian Paolo Fadini
Jul 1, 2019·Metabolism: Clinical and Experimental·Anastasia-Stefania Alexopoulos, John B Buse
Aug 29, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Yan ZhouQiuhe Ji

❮ Previous
Next ❯

Software Mentioned

stata
excel

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.